
A UK-trained physician with over 40 years of clinical and governance experience, Dr Singh upholds NeurAsia’s commitment to scientific integrity and ethical excellence across all programs.

A recognized leader in clinical trial strategy and innovation, Dr Agarwal brings ASX and NASDAQ biotech expertise to NeurAsia’s global trial execution.

Dr Marne is a dual-trained radiologist and medical executive overseeing site medical operations, imaging protocols, and safety reviews.

Umeera drives group-level finance, tax strategy, and operational efficiency across NeurAsia’s multinational platform with a focus on R&D optimization.

Darryl brings decades of CRO and biotech leadership from the UK and ANZ region, ensuring execution excellence and sponsor satisfaction across all sites.

Sheann oversees NeurAsia’s IMP operations, including licensing, storage, and distribution of controlled substances across Asia-Pacific.

Amrit contributes to the development of protocols, IBs, and trial documentation with structured clarity and regulatory alignment.